Combination therapy in a transgenic model of Alzheimer's disease
- 1 December 2013
- journal article
- Published by Elsevier in Experimental Neurology
- Vol. 250, 228-238
Abstract
No abstract availableKeywords
Funding Information
- NIA (R01AG031896)
This publication has 33 references indexed in Scilit:
- A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer diseaseNeurology, 2011
- Detection of increased scyllo-inositol in brain with magnetic resonance spectroscopy after dietary supplementation in Alzheimer’s disease mouse modelsNeuropharmacology, 2010
- Anti-inflammatory treatment in AD mice protects against neuronal pathologyExperimental Neurology, 2010
- Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled TrialJAMA, 2009
- Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaquesProceedings of the National Academy of Sciences, 2009
- Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behaviorBehavioural Brain Research, 2008
- Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryNature Medicine, 2008
- Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer miceBrain Research, 2008
- Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein miceBMC Neuroscience, 2007
- Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse modelNature Medicine, 2006